For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.


USD 29.02
As of 2023/09/22

1-Day Change
USD -0.07 (-0.24%)
As of 2023/09/22

Morningstar Rating

As of 2023/08/31

Key investment risks:

  • The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
  • Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related


  • risks. In extreme market conditions, you may lose your entire investment.
  • The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
  • The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
  • Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.




The Fund's investment objective is to seek long-term growth of capital.
The Fund pursues its objective by investing at least 80% of its net asset value in equities located anywhere in the world and selected for their growth potential.
The Fund will invest at least 80% of its net asset value in companies that have a life sciences orientation. Companies with a 'life sciences orientation' include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences.
The aggregate amount of the Fund which may be invested in securities traded on the developing markets is 20% of the net asset value of the Fund and no more than 10% of the net asset value of the Fund may be invested in securities traded on any one developing market.


  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care


Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.


Cumulative Performance (%)
As of 2023/08/31
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
H2 USD -1.41 2.66 7.04 2.87 13.84 20.20 49.65 536.83
Calendar Year Returns (%)
As of 2023/06/30
2022 2021 2020 2019 2018
H2 USD -2.89 6.35 25.23 28.95 3.48
Initial Charge 0.00%
Annual Charge 0.80%
Ongoing Charge
(As of 2023/06/30)


Top Holdings (As of 2023/08/31)
UnitedHealth Group Inc 6.09
Eli Lilly & Co 4.77
AstraZeneca PLC 3.93
Novo Nordisk A/S 3.58
Sanofi 2.94
Merck & Co Inc 2.83
Abbott Laboratories 2.63
AbbVie Inc 2.47
Sarepta Therapeutics Inc 2.44
Thermo Fisher Scientific Inc 2.43
Total 34.11
Sector Allocation % OF FUND % OF FUND (As of 2023/08/31)
Regional Allocation % OF FUND % OF FUND (As of August 31, 2023)